Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE rejects use of kidney cancer drugs

  • Comment

NICE will not approve bevacizumab (Avastin), sorafenib (Nexavar) and temsirolimus to treat kidney cancer patients

NICE had received appeals from five organisations to make the drugs the first treatment for people suffering from advanced kidney cancer, or cancer affecting many different areas of the body.

The also declined the approval of sorafenib and sunitinib (Sutent) as secondary treatments.

Welsh health minister Edwina Hart approved all four drugs for Wales in January, and it is unknown how NICE’s decision will affect patients already using them there.

The appealing organisations were Roche, Wyeth Pharmaceuticals, the James Whale Fund for Kidney Cancer and a joint appeal from the Rarer Cancers Forum and Macmillan Cancer Support.

Professor Peter Littlejohns, clinical and public health director at NICE, said: “We recommended the use of sunitinib for first line renal cancer in March 2009, so one of these new treatments is now available.

“The evidence to support the use of the other first and second line treatments isn’t strong enough to justify using NHS funds, which could be used for other cancer treatment programmes or in other treatment areas.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.